Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 966,110 $ 1,653,369
General and administrative 757,281 871,675
Total operating expenses 1,723,391 2,525,044
Loss from operations (1,723,391) (2,525,044)
Interest income 82,165 90,488
Net loss (1,641,226) (2,434,556)
Other comprehensive income (loss):    
Foreign currency translation loss (835) (10,800)
Unrealized gain on investments 19,198 33,645
Comprehensive loss $ (1,622,863) $ (2,411,711)
Net loss per share:    
Basic and diluted (in dollars per share) $ (0.1) $ (0.19)
Weighted average shares outstanding:    
Basic and diluted (in shares) 15,979,816 13,105,831